4 Papers
9 Citations
Yanfang Yang is an academic researcher from Tianjin Medical University Cancer Institute and Hospital. The author has contributed to research in topics: Breast cancer & Lung cancer. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune
TL;DR: Ginsenoside Rg3 could be regarded as a new agent targeting PD-L1 in chemotherapy refractory NSCLC and inhibit the growth and alleviate the resistant to cisplatin of A549/DDP cells.
121
[Efficacy of lapatinib versus trastuzumab in neoadjuvant therapy of HER-2 positive breast cancer: a meta-analysis].
TL;DR: Lapatinib can not replace trastuzumab as a first-choice agent in neoadjuvant therapy of HER-2 positive breast cancer and lapatinib plus trastizumab achieves better pCR than trastzumab so that it and may become aFirst-choice of neoadJuvant therapy for Her-2positive breast cancer regardless of economic affordability for patients.
5
Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis
TL;DR: It is demonstrated that capecitabine monotherapy could be the first choice for ABC pretreated with anthracycline and taxane due to its efficacy and low toxicity.
3
A case of tonsillar metastasis from breast cancer and literature review.
TL;DR: This poster presents a probabilistic method to identify which types of cancers can be passed through a person’s immune response to conventional chemotherapy and which methods are more likely to cause cancer progression.
1